Managing bioburden is essential to protecting patients and meeting the standards of global regulatory bodies
In medical device manufacturing, controlling bioburden prior to sterilisation is a non-negotiable part of ensuring product safety and regulatory compliance. For Class I, II and III medical devices, managing bioburden is essential to protecting patients and meeting the standards of global regulatory bodies. However, bioburden control can often be a misunderstood or underestimated aspect of production.
Pre-sterilisation controls must be integrated throughout the entire production lifecycle, not simply applied at the end. From material selection and storage to cleanroom behaviour and in-process handling, every step matters. Understanding how bioburden originates, how it spreads, and how to control it is vital for robust and repeatable device manufacture.
What is bioburden and why does It matter?
Bioburden refers to the number of viable microorganisms on a medical device or component prior to sterilisation. These microorganisms can include bacteria, fungi, spores, and other biological contaminants. While terminal sterilisation methods such as ethylene oxide (EtO) or gamma irradiation are highly effective, they are not a substitute for proper contamination control.
Excessive bioburden levels can reduce the effectiveness of sterilisation, increase sterility assurance testing failures, and even delay product release. Worse still, bioburden can alter material performance, especially in absorbent polymers or drug-contacting surfaces, compromising functionality or shelf life.
Key sources of bioburden in medical manufacturing
Bioburden can be introduced through raw materials, human interaction, ambient air, water, equipment surfaces, or even packaging materials. If these factors are not actively monitored and controlled, contamination can persist and amplify throughout the assembly line.
At Europlaz, we often find that bioburden risks increase when devices are handled excessively or transferred between uncontrolled environments. Poor gowning practices, inadequate cleaning schedules, or inconsistent operator behaviour can also elevate microbial load within a cleanroom.
Best practices for managing bioburden before sterilisation
Managing bioburden begins with rigorous planning and ends with disciplined execution. Cleanroom design must support unidirectional flow, with clearly defined zones for gowning, material entry, and exit. Materials and components should be stored in sealed, clean containers, with traceability records maintained for every batch.
Personnel must be trained to follow strict gowning protocols, limit unnecessary motion, and avoid overhandling of parts. Equipment should be validated for cleanroom use and undergo scheduled sanitisation. Air handling units must maintain ISO-classified particulate and microbial levels, with regular environmental monitoring to verify compliance.
In-process controls such as bioburden testing of components, swabbing of surfaces, and monitoring of operator behaviour help to detect potential risks early. These procedures should be documented and linked directly to the device master record (DMR) and quality system.
Bioburden and regulatory requirements
The ISO 11737 series sets the international standard for determining bioburden on medical devices. ISO 11737-1 outlines the quantification method, while ISO 11737-2 guides the validation of sterilisation processes based on bioburden levels. In addition, manufacturers must comply with ISO 13485, which requires contamination control across all processes that affect product quality.
Understanding these standards – and integrating them into cleanroom protocols – is crucial for ensuring regulatory readiness. Failing a bioburden test late in the process can result in batch rejections, increased costs, or loss of certification.
How Europlaz supports bioburden control
Europlaz takes a proactive approach to managing bioburden at every stage of manufacturing. From our ISO Class 7 cleanrooms to our validated gowning procedures and documented cleaning regimes, we implement best practices to reduce microbial load. Our team works closely with clients to assess product-specific risks and establish environmental monitoring plans that ensure ongoing compliance.
For products requiring terminal sterilisation, we ensure that pre-sterilisation bioburden levels remain consistent and within acceptable ranges, thereby protecting sterilisation efficacy and product quality.
Ensure your devices meet the highest standards
Managing bioburden is not an optional extra – it’s a foundational aspect of producing safe and compliant medical devices. From start to finish, cleanroom behaviours, process validation, and environmental controls must work together to keep microbial contamination in check.
Contact us to find out more about how Europlaz can help manage bioburden and maintain the highest levels of control throughout your device manufacturing process.
FAQs: Managing bioburden in medical device manufacturing
What is an acceptable bioburden level for medical devices?
Acceptable levels vary based on device type, sterilisation method, and regulatory pathway. Typically, levels must support a Sterility Assurance Level (SAL) of 10^-6.
How often should bioburden testing be performed?
Testing frequency depends on production volume and risk classification but should be routinely performed on incoming components and finished devices prior to sterilisation.
Can bioburden affect device functionality?
Yes. In some cases, microbial contamination can degrade materials, interfere with coatings, or impact drug delivery mechanisms.
What happens if bioburden limits are exceeded?
Exceeding limits can result in sterilisation failure, batch rejection, or regulatory noncompliance. Corrective actions include reprocessing, root cause investigation, and process revalidation.
Download our brochure
Curious to learn more? Download our brand-new company brochure to discover how Europlaz is evolving and what it means to you.
Discover Europlaz
Our UK-based ISO 13485 certified and FDA-compliant cacility means that we have complete control of the process, from under one roof. We are flexible, and resourceful, and can take on projects of any size. Our clients range from small start-ups to international blue chip medical device suppliers.
